Neurocrine Reports Positive Two-Year Phase 3 Data For Crenessity In Pediatric CAH

WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) on Monday reported positive two-year data from its Phase 3 CAHtalyst Pediatric study of Crenessity in children and adolescents with classi...